InvestorsHub Logo
icon url

jessellivermore

07/31/18 8:56 AM

#135594 RE: me33 #135590

me33

Quote: "We need stat. significant PE. Period."

Please do not take my hypotheticals for what I believe will be the case...If I thought the PE was going to fail (I don't) then I would not be holding my long position..

What I am doing is considering the worst case scenarios and I feel even under the very worst situation R-I has a safety net that most investors are not considering..My own experience in using Vascepa on patients suggests the protective effects of V may be greater than the preventative effects. What I mean by that is V may be effective at reducing CVD events, but is even more effective at limiting the extent of injury caused by the event...

":>) JL



icon url

oneragman

07/31/18 8:58 AM

#135595 RE: me33 #135590

me33, maybe you or someone else can explain to me how they are determining the PE. They are measuring "time to event". I don't take that as strictly looking at the number of events only in the 2 groups and doing a ratio, although that would be an effect of time. In cancer trials, most of the time everyone dies, but they are looking at extending life, sometimes by only months and the trail is considered a success. Am I reading something into this that is just not there?